Taliwas sa paniniwala ng publiko: Nikotina, hindi sanhi ng sakit, cancer

Taliwas sa paniniwala ng publiko: Nikotina, hindi sanhi ng sakit, cancer

November 8, 2022 @ 11:49 AM 4 weeks ago


HINDI kailanman naging dahilan ng sakit at cancer ang nicotine o nikotina taliwas sa karaniwang pang-unawa at pagkakaalam ng publiko.

Ito ang binigyang diin ng mga  health policy expert.

“There is no loss of control. It does not impair cognitive function. In fact, it may even enhance it.  And nicotine does not produce disease. It is not carcinogenic,” ayon kay Michael Ogden,  isang regulatory at industry expert ng consulting group Chemular, nag-moderate sa kamakailan lamang na  Global Tobacco & Nicotine Forum (GTNF) sa Washington D.C.

“Unfortunately, a lot of information on the Internet about nicotine does not help smokers make informed decisions. “It is not really helping people who smoke understand how to use the products that are available including lower-risk tobacco nicotine products as well as nicotine replacement therapy (NRT) to actually quit smoking,” ayon naman kay  Karen Gerlach, isang regulatory scientist sa Womble Bond Dickinson (U.S.) LLP.

Binigyang diin ni Gerlach  ang pangangailangan na gawing available ang tamang impormasyon hinggil sa nikotina upang tulungan ang milyong smoker o naninigarilyo na tumigil na at sa halip ay lumipat  sa lower-risk alternatives gaya ng  heated tobacco products at e-cigarettes.

“These alternatives deliver nicotine without burning tobacco. They produce aerosol instead of smoke,” giit ni Gerlach.

Ang proseso aniya  ng pagsunog sa tabako sa sigarilyo ay napag-alaman na nakapagpo-produce ng  7,000  na “harmful at  potentially harmful chemicals.”

Ang heated tobacco products ay  pinapainit ang  tabako habang ang  e-cigarettes naman ay pinapainit ang e-liquid na maaaring mayroon o hindi naglalaman ng nikotina.

Ang dalawang produkto ay nag-aalis ng pagkasunog at hindi sinusunog ang tabako.

“There is a need to get accurate, scientically-based information out to people who smoke to help them make the decisions that are right for them and help them quit smoking. We need to figure out how to get accurate, scientifically-based information to smokers,” wika nito sa isinagawang GTNF.

Ayon naman kay Ogden, marami ang  “misinformation” ukol sa nicotine na inihahalintulad at ginagawa pang kasing kahulugan ng “smoking at addiction.”

“A simple lie is far easier to believe than the complex truth, and we are looking at the complex truth here,” anito.

Aniya, may ilang positibong epekto ng nikotina ang tinalakay sa iba’t ibang literatura o panulatan ng ilang dekada.

“Nicotine has a paradoxical effect. Nicotine is a stimulant; it induces pleasure and improves concentration, reaction times and performance on certain tasks. Nicotine can also reduce stress and anxiety. It stimulates and reduces stress in many people,” ani Ogden.

Ani Ogden, hindi lamang matatagpuan ang nikotina sa  tobacco products dahil maaari itong i-purify bilang caffeine sa pharmaceutical standards.

“Nicotine is in nicotine replacement therapy which is sold over-the-counter,” ayon kay Ogden.

“If nicotine was all that dangerous, I don’t think this would be true, particularly not in over-the-counter medication,” dagdag na pahayag ni Ogden.

“We really need information that is easily accessible to people, that givesthem these comparative risks,” ang winika naman ni Gerlach,  nag-trabaho sa larangan ng tobacco control  sa loob ng 25 taon, may posisyon sa federal government, isang malaking non-profit at pribadong sektor.

Si Gerlach ay mayroong “applied at  practical experience” sa  lahat ng aspeto ng agham mula sa pagsasagawa ng basic laboratory research hanggang sa paga-aplay ng scientific evidence para sa advance regulatory decisions at public policy.

Kabilang na rito ang “design, implementation at reporting” sa lahat ng aspeto ng post-market surveillance na ni-require o hiningi  ng regulatory agencies.

Nakatuon si Gerlach sa premarket and post-market regulatory submissions para sa sa  tobacco harm reduction products, kabilang na ang  “study design, implementation, analysis at reporting.”

Aniya, napag-alaman sa  ilang international studies na ang taong iniisip at inaakala na ang e-cigarettes o NRT na may mataas na “comparative risks” ay mas malamang na hindi subukan  ang mga nasabing produkto para matulungan silang mag-quit o huminto.

Aniya,  napag-alaman sa kamakailan lamang na pag-aaral mula sa  Population Assessment of Tobacco and Health (PATH) report  na  hindi lamang ang mga taong mayroong “high risk perceptions” sa  low-risk products ang malabong subukan at i-adopt ang mga ito at walang katiyakan na gamitin ito para ganap na lumipat.

“Even if they did switch completely, they were less likely to stay switched, and more likely to return to smoking,” ani  Gerlach.

Sa kabilang dako, hinamon naman ni Gerlach ang nicotine industry at  mga health regulator na magbigay ng tamang impormasyon upang tulungan ang mga smokers o mga naninigarilyo.

“I think the role of the industry is to continue to develop high-quality, lower-risk products that are acceptable alternatives to cigarettes for people who smoke cigarettes, and then get those through regulatory process which means conducting high level science,” anito.

“Once they get that authorization, they need to monitor these products in the market and continue to demonstrate they remain appropriate for the protection of public health,” wika pa ni Gerlach.

Samantala, hindi naman lingid sa kaalaman ni Gerlach na may limitasyon  ang komunikasyon na maaaring magawa ng industriya para maabot ang  mas marami pang mamimili.

“I wish they had a better voice particularly when they got Modified Risk Tobacco Product authorization to be able to speak about that. Consumers need to have that information,” ayon kay Gerlac sabay sabing “But the reality right now is that they are not able to do that.”

Sinabi pa nito na dapat lamang na ipinabatid din ng  Food and Drug Administration (FDA), nakatatanggap ng lahat ng scientific evidence na ipinresenta ng industriya ang risk benefits ng  lower-risk products sa mga mamamayan.

“They certainly can communicate once they agreed there is a lower risk product. They should be able to communicate with smokers about those products and help them to understand how they may be able to transition to lower-risk products,” ani Gerlach.

“What they need to do is to utilize some of that communication arm that they have to help people who smoke understand what these products are and how these products might be able to benfit them,”  aniya pa rin.

Ang GTNF ang  itinuturing na  leading annual forum  sa buong mundo kung saan tinatalakay ang hinaharap o kinabukasan  ng “tobacco at nicotine industries.”